Skip to main content

TransCode Therapeutics, Inc. (RNAZ)

NASDAQ: RNAZ · Delayed Price · USD
2.82
-0.02 (-0.70%)
After-hours:Oct 21, 2021 5:27 PM EDT
2.84
-0.14 (-4.70%)
At close: Oct 21, 4:00 PM
Market Cap33.99M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out11.97M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume153,366
Open2.96
Previous Close2.98
Day's Range2.82 - 2.98
52-Week Range2.35 - 7.00
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About RNAZ

TransCode Therapeutics is an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. Our strategy seeks to overcome RNA-based therapeutics delivery challenges by repurposing a particle used extensively in humans for imaging purposes to deliver synthetic RNA molecules (called oligonucleotides) to cancer cells. We have created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving pat...

IndustryBiotechnology
IPO DateJul 9, 2021
CEOR. Michael Dudley
Employees2
Stock ExchangeNASDAQ
Ticker SymbolRNAZ
Full Company Profile

Financial Performance

Financial Statements

News

TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (TransCode) (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and ef...

3 weeks ago - Business Wire

RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today

TransCode Therapeutics (RNAZ) stock is rocketing higher on Thursday as investors react to positive news from a breast cancer study. The post RNAZ Stock Alert: The Breast Cancer Study News Sending TransC...

4 weeks ago - InvestorPlace

5 Penny Stocks to Watch That Exploded Today, What You Need to Know

These penny stocks exploded during today's trading session, are they worth watching or not? The post 5 Penny Stocks to Watch That Exploded Today, What You Need to Know appeared first on Penny Stocks to ...

Other symbols:AIHSBESTMTNBRWLK
4 weeks ago - PennyStocks

Here's why TransCode Therapeutics stock is up about 65% on Thursday

Shares of TransCode Therapeutics Inc (NASDAQ: RNAZ) climbed by 65% on Thursday morning as the oncology company said in its press release that the preclinical research supporting its lead candidate, TTX-...

4 weeks ago - Invezz

Why Are TransCode Therapeutics Shares Shooting Higher On Thursday?

TransCode Therapeutics Inc (NASDAQ: RNAZ) is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology.  Related:   TransCode Therapeutic...

4 weeks ago - Benzinga

TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Pote...

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective deli...

4 weeks ago - Business Wire

TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective del...

1 month ago - Business Wire

TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development

TransCode Therapeutics Inc (NASDAQ: RNAZ) has received a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support developing TTX-MC138. TTX-MC138 is TransCode's lead therapeuti...

2 months ago - Benzinga

TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX...

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a platform company solving the challenge of RNA delivery in oncology, today announced that it has been awarded a Fast-Track Small Bu...

2 months ago - Business Wire

TransCode Therapeutics, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters' O...

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), an emerging RNA oncology company created on the belief that cancer can be defeated through the intell...

3 months ago - Business Wire

TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics IPO Pricing Release

3 months ago - Business Wire

Oncology biotech Transcode Therapeutics files for a $30 million IPO

Transcode Therapeutics, a preclinical biotech developing RNA-based therapies for cancer, filed on Friday with the SEC to raise up to $30 million in an initial public offering.

7 months ago - NASDAQ

TransCode Therapeutics IPO Registration Document (S-1)

TransCode Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

7 months ago - SEC